Handelsavisen
prelaunch
Companies Healthcare 600085.SS
60
600085.SS Shanghai Stock Exchange Pharmaceuticals

600085.Ss

¥25,23
Open in Charts → Attach watcher ⌖
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
34,6B CNY
P/E
EV / Rev
Div yield
3,60 %
Op margin
11,8 %
ROE
8,7 %
Net margin
6,9 %
Debt / equity
0,31
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.

Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY8 analysts
7 buy0 hold1 sell
Avg 12m price target36,48

Analyst recommendations

8 analysts · consensus Buy
Buy7
Hold0
Sell1
12-month price target
36,48
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
8 analysts · indicative
Ownership
not yet wired
Profitability
8,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 600085.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 600085.SS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a relatively strong liquidity position, with a current ratio of 3.59, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, the liquidity risk is assessed as medium, and the company has a negative net cash position after subtracting total debt, which could pose a challenge in the event of a liquidity crunch.

    Profitability metrics show a return on equity (ROE) of 8.71%, which is a strong indicator of the company's ability to generate returns for its shareholders. However, the return on assets (ROA) is lower at 3.88%, suggesting that the company may not be utilizing its assets as efficiently as it could. The gross profit margin is 42.3%, and the operating margin is 11.75%, both of which are in line with industry norms.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification could expose the company to higher risk if market conditions in its primary market deteriorate.

    The company's growth trajectory is expected to remain stable, with no significant changes in revenue or earnings projected for the next fiscal year. The company's capital expenditure is negative, indicating that it is generating more cash from operations than it is spending on new assets.

    The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified. The risk assessment indicates that the company is not currently facing any major financial or operational risks that would significantly impact its operations or financial performance.

    Recent events, including analyst estimates and price targets, suggest a positive outlook for the company. The mean price target is 36.48 CNY, with a median price target of 37.46 CNY, indicating that analysts generally expect the stock to appreciate in value.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 3.59.
    • The company's ROE of 8.71% is strong, but its ROA of 3.88% is relatively low.
    • The company's revenue is concentrated in a single business segment, which could increase its risk exposure.
    • The company is expected to maintain a stable growth trajectory with no significant changes in revenue or earnings projected.
    • Analysts have a generally positive outlook for the company, with a mean price target of 36.48 CNY.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥25,23
    Market cap
    ¥34.60B
    Enterprise value
    ¥38.86B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    14.4x
    P / B
    2.5x
    P / Tangible book
    2.5x
    Tangible book
    ¥13.66B
    Net cash
    -¥4.26B
    Current ratio
    3.6
    Debt / equity
    0.3
    ROA
    3.9%
    ROE
    8.7%
    Cash conversion
    226.0%
    CapEx / revenue
    -2.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    1,10
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    8
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-06 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate1,10
    Revenueno estimateno estimate18,5B CNY
    Operating incomeno estimateno estimate2,6B CNY
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution8 analysts
    Strong buy3
    Buy4
    Hold0
    Sell1
    Strong sell0
    12-month price target¥36,48 · Median ¥37,46
    Low ¥25,00High ¥45,54
    Operating income · consensus2,6B CNY
    EPS surprise
    −21,3 %
    reported vs consensus · miss
    Revenue surprise
    −7,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low¥25,00
    Mean¥36,48
    Median¥37,46
    High¥45,54
    Spot¥25,23
    +44.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin11,8 %Above median
    Net Margin6,9 %Above median
    ROE8,7 %Above median
    Capex / Rev-2,1 %Above median
    D/E0,31Below median
    Cash Conv2,26Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • 600085.SS Market data — financials · 2026-05-27
    • Beijing Tong Ren Tang Co Ltd Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    600085.SSCanonical
    Shanghai Stock Exchange · CNY

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage